Anita ChandraAnita is a medic who obtained her primary medical degree from the University of Cambridge in 1998. Following general medical training where she obtained membership of the Royal College of Physicians (MRCP), she commenced her training in Clinical Immunology, initially in Newcastle upon Tyne and soon thereafter, at Addenbrooke’s hospital in Cambridge. She subsequently obtained her Fellowship of the Royal College of Pathologists (FRCPath) and currently works as an Honorary Consultant at Addenbrooke’s hospital in Clinical Immunology. Her clinical interests involve the management and care of patients with primary and secondary immunodeficiency.
Anita obtained her PhD from the University of Cambridge following work on B cell biology and antibody diversification in the Laboratory of Molecular Biology under the supervision of Professor Michael Neuberger and Dr Cristina Rada. She is currently working as a Wellcome Trust funded Postdoctoral Clinical Fellow in the Okkenhaug lab, focusing on the role of PI3Ks in human and murine immunity and susceptibility to infections. She has a particular interest in a group of patients with an activating mutation in PI3K delta (APDS) and will be complementing basic mechanistic research in this area with clinical trials using selective PI3K delta inhibitors in patients.
Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy.
Gyori D, Lim EL, Grant FM
3 2379-3708: (2018)
Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors.
Lim EL, Cugliandolo FM, Rosner DR
3 2379-3708: (2018)
Abdelrasoul H, Werner M, Setz CS
8 2045-2322:1327 (2018)
Kishore M, Cheung KCP, Fu H
47 1097-4180:875-889.e10 (2017)
Stubbs TM, Bonder MJ, Stark AK
18 1474-760X:68 (2017)
Obesity-Induced Metabolic Stress Leads to Biased Effector Memory CD4(+) T Cell Differentiation via PI3K p110δ-Akt-Mediated Signals.
Mauro C, Smith J, Cucchi D
Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy.
Okkenhaug K, Graupera M, Vanhaesebroeck B
Eil R, Vodnala SK, Clever D
537 1476-4687:539-543 (2016)
Lucas CL, Chandra A, Nejentsev S
Nature reviews. Immunology
Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.
Coulter TI, Chandra A, Bacon CM
The Journal of allergy and clinical immunology
Roychoudhuri R, Clever D, Li P
Inhibition of Phosphoinositide 3-Kinase p110delta Does Not Affect T Cell Driven Development of Type 1 Diabetes Despite Significant Effects on Cytokine Production.
Barbera Betancourt A, Emery JL, Recino A
11 1932-6203:e0146516 (2016)